NewEdge Advisors LLC Sells 5,773 Shares of Moderna, Inc. (NASDAQ:MRNA)

NewEdge Advisors LLC reduced its holdings in Moderna, Inc. (NASDAQ:MRNA) by 42.6% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,773 shares of the company’s stock after selling 5,773 shares during the quarter. NewEdge Advisors LLC’s holdings in Moderna were worth $923,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the company. Cedar Wealth Management LLC grew its holdings in shares of Moderna by 45.0% during the first quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after buying an additional 90 shares in the last quarter. Commerzbank Aktiengesellschaft FI grew its holdings in shares of Moderna by 1.7% during the second quarter. Commerzbank Aktiengesellschaft FI now owns 5,550 shares of the company’s stock worth $660,000 after buying an additional 93 shares in the last quarter. CVA Family Office LLC grew its holdings in shares of Moderna by 21.6% during the second quarter. CVA Family Office LLC now owns 541 shares of the company’s stock worth $64,000 after buying an additional 96 shares in the last quarter. Claro Advisors LLC grew its holdings in shares of Moderna by 2.0% during the second quarter. Claro Advisors LLC now owns 5,546 shares of the company’s stock worth $659,000 after buying an additional 108 shares in the last quarter. Finally, McAdam LLC grew its holdings in shares of Moderna by 1.1% during the second quarter. McAdam LLC now owns 11,075 shares of the company’s stock worth $1,315,000 after buying an additional 117 shares in the last quarter. 75.33% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Moderna news, President Stephen Hoge sold 15,000 shares of Moderna stock in a transaction on Monday, July 15th. The stock was sold at an average price of $121.12, for a total value of $1,816,800.00. Following the completion of the transaction, the president now directly owns 1,442,089 shares of the company’s stock, valued at $174,665,819.68. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Moderna news, CFO James M. Mock sold 1,321 shares of Moderna stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total value of $104,874.19. Following the completion of the transaction, the chief financial officer now directly owns 8,600 shares of the company’s stock, valued at $682,754. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, President Stephen Hoge sold 15,000 shares of Moderna stock in a transaction on Monday, July 15th. The shares were sold at an average price of $121.12, for a total value of $1,816,800.00. Following the completion of the transaction, the president now directly owns 1,442,089 shares of the company’s stock, valued at $174,665,819.68. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 77,469 shares of company stock valued at $9,177,545. Insiders own 15.70% of the company’s stock.

Moderna Stock Performance

NASDAQ:MRNA opened at $58.72 on Tuesday. The stock has a market cap of $22.50 billion, a P/E ratio of -3.75 and a beta of 1.66. The stock has a 50 day simple moving average of $77.18 and a 200 day simple moving average of $107.72. The company has a current ratio of 4.09, a quick ratio of 3.92 and a debt-to-equity ratio of 0.05. Moderna, Inc. has a 1-year low of $58.33 and a 1-year high of $170.47.

Moderna (NASDAQ:MRNA) last released its quarterly earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share for the quarter, topping the consensus estimate of ($3.47) by $0.14. The business had revenue of $241.00 million during the quarter, compared to analysts’ expectations of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The firm’s revenue for the quarter was down 29.9% compared to the same quarter last year. During the same period last year, the firm posted ($3.62) EPS. Research analysts anticipate that Moderna, Inc. will post -9.86 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on MRNA shares. JPMorgan Chase & Co. downgraded Moderna from a “neutral” rating to an “underweight” rating and decreased their price objective for the stock from $88.00 to $70.00 in a report on Friday, September 13th. Piper Sandler decreased their price target on Moderna from $157.00 to $115.00 and set an “overweight” rating for the company in a research note on Friday, September 13th. The Goldman Sachs Group decreased their price target on Moderna from $178.00 to $139.00 and set a “buy” rating for the company in a research note on Monday, September 16th. Hsbc Global Res upgraded Moderna from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 28th. Finally, Jefferies Financial Group downgraded Moderna from a “buy” rating to a “hold” rating and decreased their price target for the company from $120.00 to $65.00 in a research note on Friday, September 13th. Two analysts have rated the stock with a sell rating, thirteen have given a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Moderna currently has an average rating of “Hold” and a consensus price target of $100.44.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.